Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH

Claus Roehrborn, S. A. Kaplan, H. Lepor, W. Volinn

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Data from phase 3 studies (NCT00224107, NCT00224120) of silodosin for treatment of BPH symptoms were analyzed to examine the relationship between treatment efficacy and occurrence of abnormal ejaculation. Men aged ≥50 years with International Prostate Symptom Scores (IPSS) ≥13 and peak urinary flow rates (Qmax) of 4-15 ml s-1 received placebo or silodosin 8 mg once daily for 12 weeks. Silodosin-treated patients were stratified by absence or presence of 'retrograde ejaculation' (RE). Groups were compared using analysis of covariance (for change from baseline) and responder analyses. Of the 466 patients receiving silodosin, 131 (28%) reported RE and 335 (72%) did not; 4 of the 457 patients receiving placebo (0.9%) reported RE. Most RE events in silodosin-treated patients (110/134; 82%) were reported as orgasm with absence of seminal emission. Silodosin-treated patients with (+) and without (-) RE showed significant improvement in IPSS, Qmax and quality of life versus placebo (P<0.02). RE + patients versus RE patients experienced numerically greater improvement, but differences were not statistically significant (P>0.05). For RE+ patients, the odds of achieving improvement of ≥3 points in IPSS and ≥3 ml s-1 in Qmax by study end were 1.75 times those for RE - patients (P=0.0127). Absence of seminal emission may predict superior treatment efficacy of silodosin in individual patients.

Original languageEnglish (US)
Pages (from-to)143-148
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Volume14
Issue number2
DOIs
StatePublished - Jun 2011

Fingerprint

Ejaculation
Urodynamics
Prostate
Placebos
Therapeutics
Orgasm
silodosin
Quality of Life

Keywords

  • a-blocker
  • BPH
  • IPSS score
  • LUTS
  • retrograde ejaculation

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. / Roehrborn, Claus; Kaplan, S. A.; Lepor, H.; Volinn, W.

In: Prostate Cancer and Prostatic Diseases, Vol. 14, No. 2, 06.2011, p. 143-148.

Research output: Contribution to journalArticle

@article{c4580bab44f44a72807642564d6aa1d3,
title = "Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH",
abstract = "Data from phase 3 studies (NCT00224107, NCT00224120) of silodosin for treatment of BPH symptoms were analyzed to examine the relationship between treatment efficacy and occurrence of abnormal ejaculation. Men aged ≥50 years with International Prostate Symptom Scores (IPSS) ≥13 and peak urinary flow rates (Qmax) of 4-15 ml s-1 received placebo or silodosin 8 mg once daily for 12 weeks. Silodosin-treated patients were stratified by absence or presence of 'retrograde ejaculation' (RE). Groups were compared using analysis of covariance (for change from baseline) and responder analyses. Of the 466 patients receiving silodosin, 131 (28{\%}) reported RE and 335 (72{\%}) did not; 4 of the 457 patients receiving placebo (0.9{\%}) reported RE. Most RE events in silodosin-treated patients (110/134; 82{\%}) were reported as orgasm with absence of seminal emission. Silodosin-treated patients with (+) and without (-) RE showed significant improvement in IPSS, Qmax and quality of life versus placebo (P<0.02). RE + patients versus RE patients experienced numerically greater improvement, but differences were not statistically significant (P>0.05). For RE+ patients, the odds of achieving improvement of ≥3 points in IPSS and ≥3 ml s-1 in Qmax by study end were 1.75 times those for RE - patients (P=0.0127). Absence of seminal emission may predict superior treatment efficacy of silodosin in individual patients.",
keywords = "a-blocker, BPH, IPSS score, LUTS, retrograde ejaculation",
author = "Claus Roehrborn and Kaplan, {S. A.} and H. Lepor and W. Volinn",
year = "2011",
month = "6",
doi = "10.1038/pcan.2010.46",
language = "English (US)",
volume = "14",
pages = "143--148",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH

AU - Roehrborn, Claus

AU - Kaplan, S. A.

AU - Lepor, H.

AU - Volinn, W.

PY - 2011/6

Y1 - 2011/6

N2 - Data from phase 3 studies (NCT00224107, NCT00224120) of silodosin for treatment of BPH symptoms were analyzed to examine the relationship between treatment efficacy and occurrence of abnormal ejaculation. Men aged ≥50 years with International Prostate Symptom Scores (IPSS) ≥13 and peak urinary flow rates (Qmax) of 4-15 ml s-1 received placebo or silodosin 8 mg once daily for 12 weeks. Silodosin-treated patients were stratified by absence or presence of 'retrograde ejaculation' (RE). Groups were compared using analysis of covariance (for change from baseline) and responder analyses. Of the 466 patients receiving silodosin, 131 (28%) reported RE and 335 (72%) did not; 4 of the 457 patients receiving placebo (0.9%) reported RE. Most RE events in silodosin-treated patients (110/134; 82%) were reported as orgasm with absence of seminal emission. Silodosin-treated patients with (+) and without (-) RE showed significant improvement in IPSS, Qmax and quality of life versus placebo (P<0.02). RE + patients versus RE patients experienced numerically greater improvement, but differences were not statistically significant (P>0.05). For RE+ patients, the odds of achieving improvement of ≥3 points in IPSS and ≥3 ml s-1 in Qmax by study end were 1.75 times those for RE - patients (P=0.0127). Absence of seminal emission may predict superior treatment efficacy of silodosin in individual patients.

AB - Data from phase 3 studies (NCT00224107, NCT00224120) of silodosin for treatment of BPH symptoms were analyzed to examine the relationship between treatment efficacy and occurrence of abnormal ejaculation. Men aged ≥50 years with International Prostate Symptom Scores (IPSS) ≥13 and peak urinary flow rates (Qmax) of 4-15 ml s-1 received placebo or silodosin 8 mg once daily for 12 weeks. Silodosin-treated patients were stratified by absence or presence of 'retrograde ejaculation' (RE). Groups were compared using analysis of covariance (for change from baseline) and responder analyses. Of the 466 patients receiving silodosin, 131 (28%) reported RE and 335 (72%) did not; 4 of the 457 patients receiving placebo (0.9%) reported RE. Most RE events in silodosin-treated patients (110/134; 82%) were reported as orgasm with absence of seminal emission. Silodosin-treated patients with (+) and without (-) RE showed significant improvement in IPSS, Qmax and quality of life versus placebo (P<0.02). RE + patients versus RE patients experienced numerically greater improvement, but differences were not statistically significant (P>0.05). For RE+ patients, the odds of achieving improvement of ≥3 points in IPSS and ≥3 ml s-1 in Qmax by study end were 1.75 times those for RE - patients (P=0.0127). Absence of seminal emission may predict superior treatment efficacy of silodosin in individual patients.

KW - a-blocker

KW - BPH

KW - IPSS score

KW - LUTS

KW - retrograde ejaculation

UR - http://www.scopus.com/inward/record.url?scp=79956156019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956156019&partnerID=8YFLogxK

U2 - 10.1038/pcan.2010.46

DO - 10.1038/pcan.2010.46

M3 - Article

C2 - 21135869

AN - SCOPUS:79956156019

VL - 14

SP - 143

EP - 148

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 2

ER -